FindTrial
Sign In

Elevated fibrinogen and fibrin degradation product were associated with poor outcome in COVID-19 patients

Elevated fibrinogen and fibrin degradation product were associated with poor outcome in COVID-19 patients - Elevated fibrinogen and fibrin degradation product were associated with poor outcome in COVID-19 patients

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000041428
Enrollment
2000
Registered
2020-08-16
Start date
2020-05-05
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

None listed

Sponsors

Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: year of publication, location, study design, peer-reviewed publication status, severity measurement, and fibrinogen and FDP level in each comparison group

Exclusion criteria

Exclusion criteria: 1 incorrect patient population; 2: not reported relevant exposure (coagulation profile not available) 3: not reported relevant outcomes; 4 : review; 5: editorial; 6: duplicate; 7: case report; 8: not in english

Design outcomes

Primary

MeasureTime frame
Elevated fibrinogen and FDP level on admission were associated with an increase risk of poor outcomes in COVID-19 patients.—

Countries

Asia(except Japan)

Contacts

Public ContactMaya Ayun

Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya Department of Cardiology and Vascular Medicine

maya.qurota.ayun-2019@fk.unair.ac.id6281262208630

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026